THTim Hörmann

Tim Hörmann

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tim Hörmann has a total of 19 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Structural optimization of drug molecules with incrementally trained language models

    by Tim Hörmann, Domenic Mayer, Max Lewandowski, Andrea Hunklinger, Thomas Wein, Daniel Merk

    Automating structural optimization of drug molecules for on-target potency by machine learning is an open challenge in chemistry. Here, we capitalize on the ability of chemical language models (CLMs) to learn from sequential data and design new molecules with desired properties. We establish a training strategy mimicking the learning trajectory of a drug discovery program. Incremental CLM fine-tuning with increasingly potent template molecules from a given structure-activity relationship (SAR) series successfully biases the model to design highly active analogues. Prospective application of this technique to ligand development enables the data-driven design of molecules exceeding known representatives of given bioactive chemotypes in potency without external scoring. Our results reveal an ability of CLMs to capture SAR patterns and long-range dependencies, and to exploit SAR knowledge in designing analogues with improved on-target activity de novo corroborating their applicability to structural optimization of drug molecules.


  • Open Access

    Bioactivity prediction with chemical language models trained on labeled molecules

    by Laura Isigkeit, Tim Hörmann, Vittorio Lembo, Johanna Ehrler, Ewgenij Proschak, Francesca Grisoni, Daniel Merk

    Deep learning models trained with chemical string representations such as SMILES, referred to as chemical language models (CLMs), can learn chemical features relevant for molecular characteristics like bioactivity. For this purpose, CLMs are typically fine-tuned with active molecules to achieve a task-specific bias towards a region of interest in the chemical space. Here, we present a way to augment CLM development with inactive molecules by incorporating an activity label for self-supervised learning. We capitalize on this activity information and establish a CLM for bioactivity prediction of drug molecules. Retrospective evaluation of this model demonstrated superior target prediction performance and prospective application identified multiple novel modulators for pharmacologically relevant targets with innovative features. The model also robustly predicted activity profiles of approved and experimental drugs and the activity label allowed extraction of structure-prediction relationships as new opportunity to improve explainability of CLMs. These results expand the scope of CLMs and corroborate their use for bioactivity prediction.

  • Open Access

    Automated design of multi-target ligands by generative deep learning

    by Laura Isigkeit, Tim Hörmann, Espen Schallmayer, Katharina Scholz, Felix F. Lillich, Johanna H. M. Ehrler, Benedikt Hufnagel, Jasmin Büchner, Julian A. Marschner, Jörg Pabel, et al.

    Generative deep learning models enable data-driven de novo design of molecules with tailored features. Chemical language models (CLM) trained on string representations of molecules such as SMILES have been successfully employed to design new chemical entities with experimentally confirmed activity on intended targets. Here, we probe the application of CLM to generate multi-target ligands for designed polypharmacology. We capitalize on the ability of CLM to learn from small fine-tuning sets of molecules and successfully bias the model towards designing drug-like molecules with similarity to known ligands of target pairs of interest. Designs obtained from CLM after pooled fine-tuning are predicted active on both proteins of interest and comprise pharmacophore elements of ligands for both targets in one molecule. Synthesis and testing of twelve computationally favored CLM designs for six target pairs reveals modulation of at least one intended protein by all selected designs with up to double-digit nanomolar potency and confirms seven compounds as designed dual ligands. These results corroborate CLM for multi-target de novo design as source of innovation in drug discovery.